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pidemiological studies have implicated chronic
depression as an important predisposing factor for
dementia in later life.Depression has been shown to be
a common antecedent of Alzheimer’s disease,and may
be an early manifestation of dementia before the cogni-
tive symptoms become apparent.
1,2 In particular,patients
with depression who later develop dementia usually have
a poorer baseline performance in cognitive tasks.
3
Several studies have shown that depression is a risk fac-
tor for dementia,particularly Alzheimer’s disease,and
this may be particularly important if the depressive
episode occurs within 2 years of the diagnosis of demen-
tia.
3 Indeed,it has been estimated that patients with mild
cognitive impairment and depression have more than
twice the risk of developing dementia than those of the
same age but who do not have depression.This suggests
that depression may be a prodrome of dementia.
4
Both depression and dementia are associated with
inflammatory changes in the brain.The chronic inflam-
matory diseases, such as rheumatoid arthritis, are fre-
quently associated with depression,
5 while proinflamma-
tory cytokines, such as interferon α (IFNα), used
therapeutically in the treatment of hepatitis,for example,
are known to precipitate depressive episodes in psychi-
atrically nondepressed patients.
6An experimental study
has also been reported in which rats treated with IFNα
showed anxiety behavior in open field, and changes in
cytokines in both peripheral blood and in certain brain
regions.
7 Numerous clinical studies,supported by clinical
evidence, have shown that proinflammatory cytokines
are raised in the blood of depressed patients.
8 Such obser-
vations form the basis for the macrophage theory of
depression.
9
The possible link between depression, dementia, and
inflammatory changes in the brain is also supported by
clinical and experimental studies of acquired immune defi-
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Epidemiological studies show that there is a correlation
between chronic depression and the likelihood of demen-
tia in later life. There is evidence that inflammatory
changes in the brain are pathological features of both
depression and dementia. This suggests that an increase
in inflammation-induced apoptosis, together with a
reduction in the synthesis of neurotrophic factors caused
by a rise in brain glucocorticoids, may play a role in the
pathology of these disorders. A reduction in the neuro-
protective components of the kynurenine pathway, such
as kynurenic acid, and an increase in the neurodegenera-
tive components, 3-hydroxykynurenine and quinolinic
acid, contribute to the pathological changes. Such changes
are postulated to cause neuronal damage, and thereby
predispose chronically depressed patients to dementia.      
© 2006, LLS SAS Dialogues Clin Neurosci. 2006;8:163-174.ciency syndrome (AIDS).It is well established that when
human immunodeficiency virus (HIV)-infected patients
develop AIDS,a substantial proportion of the patients also
develop depression.
10 Depression is one of the early man-
ifestations of HIV dementia.
11Antiretroviral therapy was
also one of those early manifestations.
11An experimental
study in rodents showed that Efavirenz,the antiretroviral
drug used in treatment of HIV infection, induced
increased proinflammatory cytokines in the peripheral
blood and was associated with anxiety behavior and
impaired spatial memory.
12 Thus, both depression and
dementia are associated with inflammatory changes.
As there is pathological evidence that increased apoptosis
occurs in both chronic depression and dementia,resulting
in atrophic changes in the hippocampus,frontal cortex,and
other brain regions,
13-15 it has been speculated that the
increase in inflammatory mediators,such as interleukin
(IL)-1,TNFα,and prostaglandin E2 (PGE2),play a central
role in the pathology of these conditions.The results of
clinical and experimental research therefore lead to the
conclusion that an increase in apoptosis caused by inflam-
mation,together with a reduction in the synthesis of neu-
rotrophic factors such as brain-derived neurotrophic fac-
tor (BDNF) that assists in the repair of damaged neuronal
networks,provide a basis for the pathological changes that
are common to depression and dementia.The following
reviews the evidence in favor of this hypothesis.
Changes in the hypothalamic-pituitary-
adrenal axis in depression and dementia 
Stressful life events trigger neurotransmitter changes in
the brain via activation of the corticotropin-releasing fac-
tor (CRF) pathway that terminates not only within the
hypothalamus and other parts of the central endocrine
system,but also on the locus ceruleus and raphe nuclei.
16
This provides a biological link between stressful stimuli
and the changes in the endocrine,immune,and neuro-
transmitter systems that are involved in the psy-
chopathology of depression (Figure 1).
Investigations of the role of the hypothalamic-pituitary-
adrenal (HPA) axis in the psychopathology of depression
commenced over 40 years ago,when it was reported that
depressed patients have a higher circulating plasma cor-
tisol concentration than those that are not depressed.
18,19
At this time,the dexamethasone depression test (DST)
was developed to provide a functional assessment of
HPA axis activity. It was discovered that this synthetic
glucocorticoid would normally suppress the secretion of
cortisol by activating hypothalamic and pituitary gluco-
corticoid receptors,thereby suppressing the secretion of
CRF and adrenocorticotropic hormone (ACTH) which,
in turn,reduced the activation of the adrenal cortex and
the release of cortisol.The mechanism whereby these
changes occurred was explained in terms of a negative
feedback loop whereby the raised plasma glucocorticoid
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Figure 1. Relationship between stress, activation of limbic regions of the
brain by CRF, and the consequent changes in the adrenal cortex
and the sympathetic system. (+), activation, (-) inhibition. In
chronic stress or depression, the feedback inhibitory loop mal-
functions following the desensitization of the central glucocor-
ticoid receptors in the brain and immune cells. This results in
hypercortisolemia, a common feature of both major depression
and Alzheimer’s disease. Anxiety, a common comorbidity symp-
tom with major depression, is associated with the increased
activity of the central and peripheral sympathetic systems.
17 CRF,
corticotropin-releasing factor; NA, noradrenaline; AVP, arginine
vasopressin; Ach, acetylcholine; ACTH, adrenocorticotropic hor-
mone; PVN, paraventricular nucleus
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+concentration controls the further release of the steroid.
However,it soon became apparent that in patients with
major depression the negative feedback loop ceased to
function due to the desensitization of the central gluco-
corticoid receptors.The negative DST thereby became a
diagnostic marker of melancholic depression.
20
Nevertheless,it is now apparent that the DST lacks both
specificity and sensitivity for depression,
21 even though it
may still offer reliability in the assessment of the sever-
ity of depression.
22 Hypercortisolism and a negative DST
are now known to occur in patients with Alzheimer’s dis-
ease and alcoholism,for example.
23 Furthermore,it has
been estimated that only 60% of patients with major
depression demonstrate a negative DST.Nevertheless,
these findings do serve to emphasize the importance of
the HPA axis in psychiatric disorders.
It is frequently assumed that the synthetic glucocorticoids
such as dexamethasone act on glucocorticoid receptors in
an identical manner to the natural glucocorticoids such as
cortisol. However, this may not be the case.
Dexamethasone acts primarily on the glucocorticoid recep-
tors in the anterior pituitary, does not readily enter the
brain,and therefore differs substantially from natural glu-
cocorticoids that activate both mineralocorticoid and glu-
cocorticoid receptors.
24There is also evidence that,while
dexamethasone may reduce the release of CRF,it does not
suppress the release of arginine vasopressin (AVP).There
is evidence that AVP,not CRF,is the main activator of the
HPA axis due to chronic stress and major depression.
25,26
The increased action of AVP is further exacerbated by the
action of IL-1 β;chronically administered IL-1 β has been
shown to cause a shift in the role of CRF to AVP in the
activation of the anterior pituitary.
27 In addition,it has been
shown that there is an age-related increase in the colocal-
ization of AVP in CRF neurons in patients with major
depression and dementia.
28 Thus, it seems reasonable to
conclude that the hypersecretion of cortisol in patients with
depression or dementia may at least be partly a conse-
quence of an increased activation of the HPA axis by AVP.
Additional evidence for the change in the functional
activity of the pituitary gland is provided by the finding
that the adrenals and the pituitary are enlarged in those
with depression,
29,30 these changes being associated with
a hypersecretion of CRF.
31 Furthermore,the density of
the CRF receptors in the frontal cortex are reduced,pre-
sumably as a consequence of the hypersecretion of
CRF.
32,33The hypersecretion of CRF would appear to be
a state,rather than a trait,marker of depression.
34
If hypercortisolemia is a common feature of major
depression and some types of dementia, it would be
anticipated that immunosuppression would be a common
feature of these conditions.However,it is apparent that
both immunosuppression (for example,of natural killer
cell [NKC] activity) and immune activation (for exam-
ple, macrophage activation) are common features of
depression.One possible explanation is that an increased
vulnerability to environmental stress,which is a common
feature of both depression and dementia,
35 elicits a bidi-
rectional,homeostatic interaction between the endocrine
and immune systems. Thus, CRF has been associated
with humoral activation that results in an increased
release of proinflammatory cytokines.By activating the
HPA axis,proinflammatory cytokines not only further
release CRF,but also lead to glucocorticoid resistance,
thereby impairing the regulatory feedback mechanism.
Conversely,the increase in the concentration of plasma
cortisol,together with the increased sympathetic activity
that is a normal feature of the stress response,suppresses
NKC and T-cell replication.There is evidence that acti-
vation of the β-adrenoceptors on the NKC membrane,
and which results in the decrease in activity of the NKCs,
occurs independently of the activation of the HPA axis.
35
Clearly the interaction between the immune system and
the HPA axis is both complex and interdependent.
In the past 20 years,attention has focused on changes in
the hypothalamic-pituitary-adrenal axis,together with
the biogenic amine neurotransmitters noradrenaline,
serotonin, and, to a lesser extent, dopamine.
36,37 More
recently, however, it has become apparent that both
major depression and chronic stress result in more per-
sistent structural changes in the brain as a consequence
of the decrease in the synthesis of neurotrophic factors,
such as BDNF and the antiapoptotic factor bcl-2.
38These
changes are attributed to the chronic increase in brain
glucocorticoids that arise due to the desensitization of
central glucocorticoid type 2 receptors that occur as a
consequence of the reduction in the inhibitory feedback
mechanism.
39 Such effects contribute to the failure in
brain repair mechanisms which is indicated by a reduc-
tion in dendritic branching and a decrease in neurogen-
esis,particularly in the hippocampus and,to some extent,
in the frontal cortex.
40,41 Such changes,together with an
activation of the proinflammatory cytokines by chronic
stress and depression, also enhance apoptosis through
their indirect excitotoxic and metabolic actions.
42Thus
stress-induced hypercortisolemia and proinflammatory
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impaired neuronal plasticity and deficits in central neu-
rotransmission.
The possible link between hypercortisolemia and depres-
sion is further provided by the changes induced by anti-
depressants and glucocorticoid receptor antagonists such
as mifepristone.
43Thus,preliminary clinical evidence has
shown that the sensitization of the central glucocorticoid
receptors by such treatments,that results in the re-estab-
lishment of the feedback inhibition of cortisol release,are
correlated with the attenuation of the symptoms of
depression.
44
Is there a link between depression and
dementia? The clinical perspective
There is overwhelming evidence that inflammatory
changes are an important causative factor in the pathol-
ogy of Alzheimer’s disease and related dementias.
45The
increase in β amyloid (Ab) is not only a major patholog-
ical feature of such dementias,but is also responsible for
stimulating inflammatory responses in the brain.These
changes include an increased expression of cell adhesion
molecules and proinflammatory cytokines,and the acti-
vation of microglia in the brain parenchyma.
46 In vitro
studies have also demonstrated that Ab induces IL-1b
and IFNg from vascular cells,thereby inducing a cascade
of inflammatory changes.
47,48 In addition,the infiltration
of macrophages together with CD4+ and CD8+ T-cells,
from the periphery have been detected in Ab deposits in
cerebral vessels in patients with cerebral amyloid
angiopathy.
49
The combination of Ab and proinflammatory cytokines
is linked to the increase in apoptosis in the brains of
patients with dementia.
50 For example,there is evidence
that lymphocytes show a significant increase in DNA
fragmentation in Alzheimer patients when compared
with aged,but normal,controls.
51This change has been
linked to an increase in the intracellular concentration of
calcium ions,a prerequisite for apoptosis
52 that has not
been recorded in lymphocytes from aged control sub-
jects.Furthermore,apoptotic cell death is preceded by
the expression of apoptosis-associated molecules such as
p53,Fas (CD95/APO-1) and IL-1b converting enzyme.
Whereas the normal brain is partly immunologically priv-
ileged, in patients with inflammatory diseases such as
multiple sclerosis,stroke,Alzheimer’s disease,and possi-
bly major depression, Fas is widely expressed in the
brain.
53This apoptotic protein is expressed on CD4+ and
CD8+ T-cells and on NKCs.Such observations provide a
further link between the inflammatory changes in the
brain and increased apoptosis that preludes dementia.
Despite these convincing observations regarding the
inflammatory changes in patients with Alzheimer’s dis-
ease,it is somewhat surprising to find that IL-6,a major
proinflammatory cytokine that is elevated in the plasma
and cerebrospinal fluid (CSF) of patients with major
depression,has been reported to be unchanged
54 or even
decreased
55,56 in the blood of Alzheimer’s patients.Some
investigators have,however,reported that IL-6 is increased
in these patients.
57 Some of these differences may be
accounted for by the methods used to assay IL-6.Thus the
concentration of IL-6 in the serum and CSF is often at the
limit of detection,while in in-vitro studies,in which stimu-
lated lymphocytes are isolated by gradient centrifugation,
the cells are stressed which may alter their phenotype.
It has also been argued that the decrease in proinflam-
matory cytokines in Alzheimer’s disease is a consequence
of the hypercortisolemia
55 although this would not
explain why cytokines such as IL-6 remain elevated in
depressed patients where hypercortisolemia also com-
monly occurs.
The cognitive changes and dysphoria that are common
symptoms in the early stages of Alzheimer’s disease have
been correlated with the increase in proinflammatory
cytokines such as IFNα.
6 Despite the equivocal evidence
regarding the rise in plasma IL-6 concentration in
Alzheimer patients,there are reports that the IL-6 con-
centration correlates with the severity of dementia.
58
From the numerous studies of the changes in the immune
system of patients with dementias,it would appear that
the inflammatory changes can trigger an increased syn-
thesis and accumulation of Ab.
59The accumulation of Ab
then initiates a further cascade of inflammatory changes
in the brain involving proinflammatory cytokines and
neurotoxic free radicals such as nitric oxide (NO)
60;this
involves the activation of the NFkβ pathway and the
complement system.Neuronal COX 2 expression is also
increased in Alzheimer’s disease, and the resulting
increase in PGE2 contributes to the subsequent deteri-
oration in the clinical state of the patient.
61 In addition,
the rise in IL-1β may also indirectly contribute to the
cognitive deficit by inhibiting cholinergic function
62;a
deficit in acetylcholine is generally accepted as the pri-
mary neurotransmitter that is causally involved in the
cognitive and memory deficits in the dementias.
44
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166The question arises as to whether the increase in Ab is
a reflection of the rise in proinflammatory cytokines,an
important consideration if major depression predisposes
to dementia.In support of this connection,there is evi-
dence that severe head trauma in young persons can
result in a large number of amyloid plaques shortly after
the traumatic event.
63The accumulation of Ab was shown
to occur secondarily to the stress induced activation of
the microglia that precipitate the release of Il-1;the Ab
formed then stimulated the “cytokine cascade,”a key ele-
ment in the pathogenesis of dementia.
64
Further evidence in support of the hypothesis linking the
outcome of chronic depression with dementia comes
from studies on the progression of an HIV infection to
AIDS. It is well known that severe life stress, and
bereavement of a partner with AIDS,is associated with
a rapid progression of HIV to AIDS and a consequent
increase in mortality.
65 For example,it has been reported
that changes in immune function,such as a reduction in
NK cells,correlates with the incidence of depression and
the progressive deterioration in the clinical status of the
patients with HIV/AIDS
10,66,67 although not all investiga-
tors have found such an association.
68 Nevertheless,such
studies do provide possible support for the hypothesis
that impaired immune function associated with the symp-
toms of depression may act not only in the progression
of an AIDS infection but also to the onset of AIDS
dementia in those patients who do not die as a conse-
quence of secondary infections or cancer.
Changes in proinflammatory cytokines in
depression and dementia
Evidence implicating a role for the proinflammatory
cytokines in the etiology of depression has been provided
by studies on the changes in IL-1, IL-6, and TNFα in
depressed patients and also by the effects of IFNα on psy-
chiatrically normal individuals being treated for hepatitis
or a malignancy. Such studies have implicated these
cytokines as causative factors in the symptoms of major
depression. These symptoms include depressed mood,
anxiety,cognitive impairment,lack of motivation,loss of
libido,sleep disturbance,and deficits in short-term mem-
ory.Such symptoms usually disappear once the plasma
cytokine concentrations return to normal.
69These changes
appear to be a consequence of the neurotransmitter and
endocrine changes induced by the cytokines,rather than
the pathological condition for which the treatment has
been administered.
70,71 It is perhaps not surprising there-
fore to find that the symptoms of depression frequently
occur in patients recovering from a chronic infection,
those with multiple sclerosis,
72 allergies,
73 and rheumatoid
arthritis.
74 In all these situations, proinflammatory
cytokines are known to be overexpressed
75 The initial
studies linking depression with an abnormality of the
immune system,
76 impaired mitogen-stimulated lympho-
cyte proliferation,
77 and reduced NK cell activity
78 in
untreated depressed patients,showed changes that largely
returned to normal once the patient recovered from the
depressive episode. Recent research into the immune
changes occurring in depression has concentrated on
cytokines,soluble cytokine receptors,and plasma acute-
phase proteins.For example,positive acute-phase proteins
have been shown to increase while the negative acute-
phase proteins decreased in depression,changes that are
known to be a consequence of the action of IL-6 on liver
function.
79 In addition,complement proteins (C3,C4) and
immunoglobulin M are increased in depressed patients.
Such changes are evidence of immune activation involv-
ing both the inflammatory cytokines and B-cells that are
activated by the proinflammatory cytokines.Further evi-
dence of immune activation in depressed patients is pro-
vided by the studies showing that the plasma concentra-
tion of IL-1,IL-6,IFNg,soluble IL-6 and IL-2 receptors,
and the IL-1 receptor antagonist, are raised. These
changes are correlated with a rise in plasma acute-phase
proteins.
80 Effective antidepressant treatments largely
attenuate such immune changes. In addition to the
increases in proinflammatory cytokines,there is also evi-
dence of an increased number of T-helper,T-memory,acti-
vated T-cells and B-cells that act as a source of the plasma
cytokines.
81-83 From these changes,it would appear that in
depression there is an imbalance between the inflamma-
tory and the anti-inflammatory arms of the immune sys-
tem,the cytokines from the T1 pathway (such as IFNg)
becoming predominant over those of the anti-inflamma-
tory T2 (for example,IL-4) pathway.A recent study has
shown that the T3 cytokine,transforming growth factor
b1 (TGFβ1) whose function is to re-establish the balance
between the T1 and T2 pathways, is increased in
depressed patients following effective antidepressant
treatment.
84 Though TGFβ1 is reported as a regulatory
cytokine that keeps the balance between Th1 and Th2
cytokines,
85 precisely how the increases in the proinflam-
matory cytokines are attenuated by TGFβ1 in depressed
patients is unclear.
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167The role of the microglia in inflammatory
changes in the brain
Localized inflammatory responses in the brain
parenchyma have been associated with the pathogenesis
of a number of neurological disorders including
Alzheimer’s disease and Parkinson’s disease.
86,87At these
lesion sites,activated microglia release such inflammatory
mediators as TNFα and PGE2.
88 It is well-known that
PGE2 is an important mediator of inflammation.In-vitro
evidence shows that PGE2 secretion from lymphocytes of
depressed patients is increased,
89 as is the PGE2 content of
the saliva, serum, and CSF of such patients.
90,91 Of the
proinflammatory cytokines,IL-6 appears to play a key role
in the synthesis of this prostaglandin both in vitro and in
vivo.
92,93 Conversely,different types of antidepressants have
been shown to inhibit the secretion of proinflammatory
cytokines and to reduce the synthesis of PGE2.
94-96 This
raises the interesting possibility that the reduction in proin-
flammatory cytokines and inflammatory mediators such
as PGE2 in the brain may be associated with the thera-
peutic actions of antidepressants.
17As it appears that the
proinflammatory cytokines increase the inducible form of
cyclo-oxygenase (COX2) in the brain, it would be
expected that COX2 inhibitors would not only attenuate
the central inflammatory changes but also exert an anti-
depressant effect.There is some clinical evidence to sup-
port this view.Thus, rofecoxib, when administered to a
large group of patients suffering from osteoarthritis,was
found to reduce the symptoms of those who were suffer-
ing from comorbid depression;15% of the patients had
depression at the start of the study,which decreased to 3%
at the end of the period of treatment.
97 Other clinical stud-
ies have suggested that the COX2 inhibitor celecoxib has
positive effects on cognitive function in depressed
patients.
97 It should be noted that celecoxib has also been
shown to have beneficial effects as an “add-on”compo-
nent to clozapine in the treatment of schizophrenia in
patients who are only partially responding to the antipsy-
chotic medication.
98,99There are several mechanisms that
are postulated to be involved in the etiology of depression.
It is commonly assumed that a decrease in both the nora-
drenergic and serotonergic functions are causally related
to the changes in the mood, motivation, and cognitive
changes associated with the disorder,There is now exper-
imental evidence to show that the inhibition of COX2 is
associated with a rise in the synthesis of serotonin in the
cortex of the rat brain.
100 In addition, PGE2 has been
shown to reduce the release of noradrenaline from central
noradrenergic neurons,an effect that would be blocked by
the COX2 inhibitors.Thus inhibition of COX2 activity in
the brain contributes not only to the reduction in inflam-
matory changes but also to an enhancement of biogenic
amine function.PGE2 is probably one of the most potent
inflammatory mediators in terms of the initiation and
propagation of inflammation within the brain.
101 Both clin-
ical
90,102 and experimental studies have shown that there is
an increase in the tissue concentrations of PGE2 in depres-
sion and in an animal model of depression.
89 In the brain,
the microglia act as macrophages. On activation, they
release proinflammatory cytokines,PGE2,and neurotoxic
metabolites of the kynurenine pathway.
103 Recent experi-
mental evidence has shown that lipopolysaccharide (LPS),
an activator of macrophage activity and a cause of brain
inflammation,induces mitochondrial PGE2 synthase and
COX2 activity in activated microglia,thereby increasing
the synthesis of PGE2 at sites of inflammation in the
brain.
104This provides a possible mechanism to explain the
inflammatory changes in patients with depression or
dementia;changes that contribute to neurodegeneration.
Nitric oxide (NO) can also act as an inflammatory media-
tor that contributes to neurodegeneration,
105 and is raised
in the plasma of depressed patients.
106 NO is produced by
both the constitutive and inducible forms of NO synthase
(NOS) that are associated with neurons and microglia.
107-109
Recent evidence suggests that proinflammatory cytokines
activate inducible NOS,thereby increasing NO;apoptosis
results from the nitrosylation of deoxyribonucleic acid
(DNA).
110 The increase in peripheral and central
macrophage activity associated with the inflammatory
changes initiate,via the activated microglia,increases in
PGE2 and NO that further potentiate the inflammatory
changes (Figure 2).Thus in both depression and demen-
tia, PGE2, NO, and neurotoxic metabolites from the
kynurenine pathway appear to play an important role cen-
tral inflammatory processes that contribute to neurode-
generation.
Neurodegeneration and the role of 
neurotoxic metabolites of the 
tryptophan pathway
The depletion of tryptophan from the diet results in a
reduction in serotonin in the brain that correlates with
the onset of a depressed mood state.
111 Tryptophan is
metabolized by two main pathways, by tryptophan
Basic research
168hydroxylase leading to the synthesis of serotonin in the
brain and by indoleamine 2,3-dioxygenase (IDO) and
tryptophan 2,3-dioxygease (TDO) resulting in the for-
mation of kynurenine.
112,113 It has been hypothesized that
in depression the metabolism of tryptophan by IDO and
TDO is increased,thereby reducing the availability of the
amino acid to synthesize serotonin.
103TDO is located in
the liver,while IDO is found in the lungs,placenta,blood
and brain.
72,114The activity of TDO is increased by tryp-
tophan and by cortisol.As hypercortisolemia frequently
occurs in both depression and dementia, it would be
anticipated that TDO is overactive in patients with these
disorders.By contrast,IDO activity is increased by proin-
flammatory cytokines such as IL-6 and IFNg,and inhib-
ited by anti-inflammatory cytokines such as IL-4.
115,116
Thus the activities of both TDO and IDO are likely to be
increased in depression and dementia as a consequence
of the rise in circulating cortisol and the proinflammatory
cytokines.There are two main stages in the metabolism
of tryptophan following the actions of the dioxygenases.
117
Following the conversion of tryptophan to kynurenine by
IDO or TDO,kynurenine is metabolized by kynurenine
hydroxylase to the neurotoxic metabolites 3-hydrox-
ykynurenine,3-hydroxy- anthranilic acid,and quinolinic
acid.An alternative pathway involves the conversion of
kynurenine to 3-hydroxyanthranilic acid by kynureni-
nase.These form the neurodegenerative arm of the tryp-
tophan-kynurenine pathway.
Alternatively,kynurenine may be metabolized by kynure-
nine aminotransferase to the neuroprotective end prod-
uct kynurenic acid.
118The mechanisms whereby quinolinic
and kynurenic acids act as neurotoxic and neuroprotec-
tive agents respectively is related to their activation or
inhibition of the N-methyl-D-aspartate (NMDA) recep-
tor,quinolinic acid and 3-hydroxyanthranilic acids being
agonists of the NMDA receptor while kynurenic acid is
an antagonist.
119,120 It has also been hypothesized that the
imbalance between those NMDA receptor antagonist
and agonist are involved in the pathophysiology of
chronic or treatment-resistant depression.
104 In the brain,
the metabolism of tryptophan by the enzymes of the
kynurenine pathway occurs in both astrocytes and
microglia
121,122 the former producing mainly kynurenic acid
while the latter produces the neurotoxic end products 3-
hydroxy-kynurenine, 3-hydroxyanthranilic acid, and
quinolinic acid.
123Astrocytes have been shown to metab-
olize quinolinic acid and thereby reduce the neurotoxic
impact that may arise following microglia activation.
From the foregoing evidence,it can be hypothesized that
inflammatory changes in both depression and dementia
involve the activation of microglia and an increase in the
inflammatory challenge to the brain.Such changes also
occur in patients with hepatitis who have been treated
with the proinflammatory cytokine IFNα and who devel-
oped depressive symptoms as a side effect of the treat-
ment.In these patients,it has been shown that the plasma
kynurenic acid concentration was reduced,thereby sug-
gesting that the neurodegenerative metabolites were
increased.
124 More recently we have shown that similar
changes occur in the blood of patients with major depres-
sion.
125The results of this study also showed that thera-
peutically effective antidepressant treatment increased
the neuroprotective kynurenic acid in the blood in those
patients suffering from an acute episode of depression,
but not in those with chronic depression.These changes
occurred irrespective of the clinical improvement in the
symptoms of the patients.This suggests that the progress
to dementia may increase as the depression becomes
more chronic.In patients with major depression,shrink-
age of the hippocampus,
126,127 a decrease in the number of
astrocytes and a neuronal loss from the prefrontal cor-
tex,
41,128,129 and the striatum
130 have been reported. Such
findings support the view that neurodegenerative changes
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Figure 2. Relationship between the main neurodegenerative pathways
in the brain and depression. (+) Pathways that are increased in
depression, and probably dementia.
89,101,103,105,107 IDO,
indoleamine 2,3-dioxygenase; iNOS, inducible nitric oxide syn-
thase; CRF, corticotropin-releasing factor; COX 2, inducible
cyclo-oxygenase 2; PGE2, prostaglandin E2; HPA, hypothalamic-
pituitary-adrenal; NO, nitrous oxide; IL, interleukin; NOS, nitrous
oxide synthase; BDNF, brain-derived neurotrophic factor
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+occur in several discrete regions of the brain in patients
suffering from chronic depression.Furthermore,as the
astrocytes are a major source of kynurenic acid,apopto-
sis of these cells would result in a reduction in the neu-
roprotective effect of kynurenic acid.There is evidence
that in the astrocytes the kynurenine pathway is limited
due to the absence of kynurenine hydroxylase.As a con-
sequence,astrocytes only produce a very low concentra-
tion of the neurotoxin quinolinic acid and a relatively
high concentration of the neuroprotective agent
kynurenic acid.
113 Furthermore,in astrocytes IDO is pref-
erentially induced by IFNg,a cytokine that also induces
the catabolism of quinolinic acid.
113 However, it is also
apparent that the increase in the synthesis of kynurenine
by the astrocytes can indirectly contribute to the forma-
tion of quinolinic acid by the microglia.This situation
would be compounded by the increased activation of the
microglia by the proinflammatory cytokines with the con-
sequent rise in the concentration of the inflammatory
mediators PGE2 and NO.Figure 3 summarizes the path-
ways involved in the metabolism of tryptophan by the
kynurenine pathway and the relationship with inflam-
matory cytokines in depression.
The inhibition of neuronal repair mechanisms resulting
from the reduction in neurotrophic factors that follow
the rise in blood and tissue cortisol,
131 apoptosis of astro-
cytes which are the sources of several neurotrophic fac-
tors,
132 and the possible disruption of the phospholipase
D pathway that has antiapoptotic properties and is
involved in neurite formation and repair,
133 further con-
tribute to the neuronal loss.Another association between
depression and dementia is through this IDO initiated
kynurenine pathway related neurotoxicity.An immuno-
histochemical study has proven that the immunoreactiv-
ity of IDO and quinolinic acid are high in the hippocam-
pus of Alzheimer’s disease patients.
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So far,emphasis has been placed on the role of inflamma-
tory mediators and neurotoxins produced by the kynure-
nine pathway on the possible causes of the neurodegen-
erative changes in the brain that eventually develops into
dementia.Recently,experimental evidence has shown that
transgenic mice that overexpress human tau protein (a
prominent feature of different types of dementia) show
depressive-like behavior in the Forced Swim Test.This test
is widely used to predict antidepressant activity, and is
based on the observation that when rodents are placed in
a container of warm water from which they cannot escape,
they soon adopt an immobile posture.This is assumed to
reflect a state of “learned helplessness” that reflects a
depressive-like state.
135This behavioral state was reversed
by the administration of the selective serotonin reuptake
inhibitor antidepressant fluvoxamine.In-vivo microdialy-
sis studies showed that the release of serotonin from the
prefrontal cortex was reduced in the transgenic mice,an
effect that was reversed by the fluvoxamine treatment.The
results of this study suggest that transgenic mice overex-
pressing human tau protein show symptoms of depressive-
like behavior that are associated with a reduction in sero-
tonergic function.As the behavioral and neurotransmitter
changes are reversed by a selective serotonin reuptake
inhibitor (SSRI) antidepressant,it would appear that sero-
tonin may provide a link between the pathological effects
of tau protein and the subsequent depressive-like state.
It would be incautious to extrapolate from this subchronic
study in a transgenic mouse to the complex clinical situa-
tion in which multiple pathological changes contribute to
the onset of dementia. Nevertheless, the experimental
studies do provide evidence in support of the hypothesis
that the long-term outcome of chronic depression is often
dementia.Further evidence for this hypothesis comes from
the study by Steffens et al
4 who demonstrated a link
between late-onset depression and the rise in plasma
apolipoprotein E4 which is widely considered to be a risk
factor for late-onset Alzheimer’s disease. Figure 4 sum-
marizes the possible pathways leading from depression to
dementia.
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Figure 3. Outline of the kynurenine pathway, and its induction by proin-
flammatory cytokines, that results in the accumulation of the
major neurotoxic metabolite, quinolinic acid.
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Neuronal loss is a common feature of major depression
and dementia. The progress of major depression to
dementia could result from the chronic inflammatory
changes that are linked to the activation of the microglia.
The activation of inducible COX2 and NOS by the proin-
flammatory cytokines further increases the inflammatory
challenge to the brain. As there is evidence that the
kynurenine pathway is also activated by proinflamma-
tory cytokines,it seems likely that the concentrations of
the neurotoxins 3-hydroxykynurenine, 3-hydroxyan-
thranillic acids,and quinolinic acid will also increase as a
result of the activation of the microglia.The increased
apoptosis of the astrocytes,with a reduction in the avail-
ability of the neuroprotective agent kynurenic acid,fur-
ther adds to the impact of the neurodegenerative
changes.Hypercortisolemia,a common feature of both
dementia and major depression,and apoptosis of astro-
cytes decreases the synthesis of neurotrophic factors
thereby reducing neuronal repair.This process may be
further enhanced by the disruption of the phospholipase
D pathway that normally plays an important role in neu-
rite formation and neuronal repair.This hypothesis may
assist in explaining the degenerative changes in the hip-
pocampus and other brain regions that are the features
of chronic major depression. It may also explain why
chronic depression is frequently a prelude to dementia
in the elderly patient. ❏
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Figure 4. Theoretical pathway linking chronic depression to dementia.
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